GTPBP2

Across TCGA pan-cancer cohorts, GTPBP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GTPBP2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GTPBP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GTPBP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where GTPBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.838	0.966	.009	33	view →
PDAC	OS	Tertile	All	0.390	0.660	.001	24	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.626	.006	18	view →
HNSC	DFS	Quartile	II,III,IV	0.535	0.788	.014	7	view →
GBM	OS	Tertile	All	0.931	0.743	.041	1	view →
CCRCC	OS	Median	II,III,IV	0.778	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GTPBP2–LUAD (DFS)

Open the LUAD breakdown →